CovidVax show full list
COVID-19 VACCINE:

Non-replicating viral vector Ad5

researcher:
ImmunityBio + NantKwest
https://immunitybio.com/
https://nantkwest.com/
(USA)
vaccine type: Non-replicating viral vector
Distribution updates
May 27NantKwest GMP manufacturing plant available to produce vaccine at scale (by businesswire.com)
Human Testing updates (clinical trials)

PHASE 1

 

started October 19 2020

with 35 healthy volunteers aged 18-55

trial location: USA

» clinical trial details

PHASE 1

 

started February 2021

with 35 healthy volunteers aged 18-50

trial location: USA

» clinical trial details

PHASE 1

 

started February 2021

with 65 healthy volunteers aged 18-55

trial location: USA

» clinical trial details

Mar 08ImmunityBio announced that the first cohorts of their South Africa and US COVID-19 vaccine trials have received their initial doses of the company's vaccine (by businesswire.com)
Jan 19ImmunityBio will conduct initial trial of its vaccine in South Africa where a new strain has been recently identified (by immunitybio.com)
Nov 10ImmunityBio announced they have given their second generation bivalent human adenovirus vaccine in a Phase 1 trial with no serious adverse events (by businesswire.com)
Nov 09ImmunityBio's vaccine stimulates memory T-cell recall in patients previously infected with SARS-CoV-2 (by businesswire.com)
Nov 06ImmunityBio's vaccine has the potential to either provide protection for uninfected individuals or for infected patients to induce clearance of the virus (by medrxiv.org)
Oct 21ImmunityBio announced today that the first patient has been dosed in Phase 1 clinical trial of its vaccine (by businesswire.com)
Oct 15ImmunityBio has received authorization from U.S. FDA to begin phase 1 clinical trial of its vaccine (by businesswire.com)
Animal Testing updates (pre-clinical trials)
start date: July 2020
Dec 10ImmunityBio's COVID-19 vaccine protected nasal and lung airways of non-human primates against coronavirus (by businesswire.com)
Aug 03ImmunityBio announced positive preclinical results for its Ad5 vaccine against COVID-19 (by businesswire.com)
early development updates
Feb 11FDA has authorized Immunity Bio to expand Phase 1 testing of a bivalent hAD5 T-cell COVID-19 vaccine (by immunitybio.com)
Aug 24ImmunityBio and NantKwest made an agreement to jointly develop and manufacture vaccines (by businesswire.com)
Jun 01ImmunityBio's vaccine is one of 14 candidates being evaluated by Operation Warp Speed (by sciencemag.org)
Apr 14ImmunityBio and NantKwest are in active talks with FDA for vaccines to combat COVID-19 (by businesswire.com)






contact | about | ©2020 CovidVax.org project